ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentZugCRISPR Therapeutics AG
CRISPR Therapeutics AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The core activity of CRISPR Therapeutics is the development of gene therapeutic medicines, particularly through the application of CRISPR-Cas9 technology, to cure diseases at the molecular level. The company focuses on developing medicines for various diseases such as sickle cell anemia, β-thalassemia, cancer, autoimmune disorders, and regenerative medicine.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

CRISPR Therapeutics AG

Pharmaceutical Industry
✓ Offered6
CRISPR/Cas9 gene editing therapies
CRISPR/Cas9-based gene editing therapies for the treatment of severe diseases; ex vivo and in vivo programmes for genetic disorders and cell therapies.
Approved CRISPR-based therapy (CASGEVY™)
CASGEVY™ (exagamglogene autotemcel), an approved CRISPR/Cas9 gene-edited therapy for certain patients with sickle cell disease or transfusion-dependent β-thalassemia.
Treatments for hemoglobinopathies
Gene-edited blood stem cell therapies for sickle cell disease and β-thalassemia; the goal is to activate fetal hemoglobin and, with the next generation, to enable in vivo editing.
CAR T-cell therapies for oncology and autoimmune diseases
Gene-edited allogeneic CAR T-cell therapies for CD19+ malignancies and autoimmune diseases; off-the-shelf approaches with multiplex edits to improve potency, persistence and safety.
In vivo gene editing therapies
In vivo gene editing programmes using lipid nanoparticles or viral vectors to treat cardiovascular, muscle, lung and CNS diseases.
Regenerative medicine with gene-edited stem cell therapies
Gene-edited stem cell and beta-cell replacement approaches to restore tissue or organ function, currently with a focus on diabetes.
Trust & reputation

ranQ Trust Score of CRISPR Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

CRISPR Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
CRISPR Therapeutics AG scores 93.7 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.95.212%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.96.07%
CRISPR Therapeutics AG scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
CRISPR Therapeutics AG scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

CRISPR Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once CRISPR Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

CRISPR Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank CRISPR Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of CRISPR Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Baarerstrasse 14
6300 Zug

At a glance

Legal form
Corporation
UID
CHE-494.642.722
Founded
2013 · 13 years
Last commercial register change
June 11, 2026
Employees
101 to 500
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    SI
    Sarepta International Holdings GmbH
    Zug
    OT
    Orchard Therapeutics (Switzerland) GmbH
    Zug
    EL
    E2 Life Sciences AG
    Zug
    AS
    Apellis Schweiz GmbH
    Zug
    SR
    Scholar Rock Switzerland GmbH
    Zug
    PA
    PlantingSpace AG
    Zug
    IG
    Inoiv GmbH
    Zug
    WC
    Wolke, Candoo Labs
    Zug